Agree. They're also forecasting infant trial to be fully enrolled in Q2. And they will also update Phase 2 results in Q2. Based on ibrutinib accelerated approval, I'm expecting these to be key events. The FDA wants controlled trial data and the earliest possible approval. Approval before full enrollment doesn't make sense. Why risk randomization if you can get the drug commercially. My expectation is approval 4 months after the last patient is enrolled. So my bold prediction is an accelerated approval by October.